Tamoxifen and endometrial pathologies: a prospective study

Area of Science:

• Gynecology
• Oncology
• Pathology

Background:

• Tamoxifen is a widely used medication for breast cancer treatment.
• Endometrial pathologies are a known potential side effect of tamoxifen therapy.
• Monitoring for endometrial changes is crucial in patients undergoing tamoxifen treatment.

Purpose of the Study:

• To prospectively investigate the development of endometrial pathologies in women with breast cancer receiving tamoxifen.
• To assess the correlation between tamoxifen use and specific endometrial abnormalities.
• To evaluate the utility of endometrial thickness measurements in screening for these pathologies.

Main Methods:

• Prospective follow-up of 80 women with breast cancer on tamoxifen.
• Regular 6-month intervals included pelvic examinations, Pap smears, vaginal ultrasounds, and endometrial biopsies.
• Data analysis focused on endometrial findings, patient demographics, and treatment duration.

Main Results:

• Out of 67 evaluable patients, 50 were on tamoxifen for a mean of 15.8 months.
• Abnormal endometrial findings (hyperplasia, polyps, adenocarcinoma) were observed in several patients, all presenting with abnormal vaginal bleeding.
• No significant correlation was found between endometrial thickness and the presence or type of endometrial pathology.

Conclusions:

• Abnormal vaginal bleeding is a consistent symptom associated with endometrial pathologies in tamoxifen users.
• Endometrial thickness measurements alone are not a reliable indicator for screening endometrial changes.
• The routine screening value of endometrial thickness measurement for tamoxifen-treated patients remains controversial.